NCT02104011

Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers

Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: University Hospital, Bordeaux · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization. Development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors. Angiomyolipomas have been shown to regress after prolonged treatment with mTOR inhibitors (Sirolimus), but with a large proportion of secondary effects. We showed recently that beta-blockers were able to induce regression of infantile hemagiomas. Consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the presence of beta2 receptors. The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study.

Conditions

• Renal Angiomyolipomas
• Tuberous Sclerosis

Interventions

Type	Name	Description
DRUG	Propranolol

Timeline

• Start date: 2015-05-22
• Primary completion: 2017-11-22
• Completion: 2017-11-22
• First posted: 2014-04-04
• Last updated: 2018-01-23

Locations

1 site across 1 country: France